GeneDx Holdings Corp. (NASDAQ:WGS – Get Free Report) CEO Katherine Stueland sold 3,661 shares of the firm’s stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $76.37, for a total value of $279,590.57. Following the transaction, the chief executive officer now owns 62,897 shares of the company’s stock, valued at $4,803,443.89. This trade represents a 5.50 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.
Katherine Stueland also recently made the following trade(s):
- On Monday, November 18th, Katherine Stueland sold 22,307 shares of GeneDx stock. The shares were sold at an average price of $70.34, for a total transaction of $1,569,074.38.
- On Friday, November 15th, Katherine Stueland sold 23,108 shares of GeneDx stock. The stock was sold at an average price of $70.48, for a total transaction of $1,628,651.84.
- On Tuesday, October 29th, Katherine Stueland sold 2,154 shares of GeneDx stock. The stock was sold at an average price of $66.60, for a total transaction of $143,456.40.
GeneDx Price Performance
WGS stock opened at $75.43 on Friday. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.40 and a quick ratio of 2.27. The company’s 50-day moving average is $70.21 and its 200-day moving average is $45.36. The stock has a market capitalization of $2.07 billion, a PE ratio of -24.25 and a beta of 2.03. GeneDx Holdings Corp. has a 1 year low of $1.76 and a 1 year high of $89.11.
Analysts Set New Price Targets
A number of analysts have commented on the stock. The Goldman Sachs Group upped their price target on shares of GeneDx from $54.00 to $70.00 and gave the company a “neutral” rating in a research report on Wednesday, October 30th. Wells Fargo & Company raised their target price on GeneDx from $34.00 to $75.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 30th. Finally, Craig Hallum lifted their target price on GeneDx from $70.00 to $95.00 and gave the stock a “buy” rating in a report on Wednesday, October 30th. Three research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $59.33.
Check Out Our Latest Report on WGS
Institutional Trading of GeneDx
Several hedge funds have recently bought and sold shares of WGS. Vanguard Group Inc. grew its holdings in shares of GeneDx by 4.2% during the first quarter. Vanguard Group Inc. now owns 707,612 shares of the company’s stock valued at $6,460,000 after buying an additional 28,678 shares during the last quarter. Driehaus Capital Management LLC acquired a new position in GeneDx during the 2nd quarter valued at about $11,335,000. Fred Alger Management LLC bought a new stake in GeneDx during the 3rd quarter worth approximately $16,731,000. Geode Capital Management LLC raised its stake in shares of GeneDx by 8.7% in the third quarter. Geode Capital Management LLC now owns 377,631 shares of the company’s stock worth $16,030,000 after purchasing an additional 30,379 shares during the last quarter. Finally, Assenagon Asset Management S.A. bought a new position in shares of GeneDx in the second quarter valued at approximately $9,575,000. Institutional investors and hedge funds own 61.72% of the company’s stock.
About GeneDx
GeneDx Holdings Corp., through its subsidiaries, provides genomics-related diagnostic and information services. The company offers Centrellis, an AI-driven health intelligence platform that integrates digital tools and artificial intelligence allowing scientists to ingest and synthesize clinical and genomic data to deliver comprehensive health insights.
Featured Stories
- Five stocks we like better than GeneDx
- Stock Market Upgrades: What Are They?
- FinWise Bancorp’s CEO Talks Strategy Behind Fintech Success
- Health Care Stocks Explained: Why You Might Want to Invest
- Broadcom: Turning the Mag 7 Into 8 Trillion-Dollar Tech Giants
- Transportation Stocks Investing
- SoundHound AI: Can Its Meteoric Rise Sustain Into 2025?
Receive News & Ratings for GeneDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GeneDx and related companies with MarketBeat.com's FREE daily email newsletter.